Skip to content

Evaluate the Utility of the ProLung China Test in the Diagnosis of Lung Cancer

Evaluate the Utility of the ProLung China Test as Adjunctive to CT Scan in the Diagnosis of Lung Cancer

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02726633
Acronym
ProLung
Enrollment
500
Registered
2016-04-04
Start date
2015-05-31
Completion date
2017-12-31
Last updated
2017-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Pulmonary Nodules, Solitary Pulmonary Nodule

Brief summary

A Study to evaluate the utility of the ProLung China Test as an adjunct to CT scan in the diagnosis of lung cancer.

Detailed description

This Study will assess the stability of the ProLung China Test classification algorithm when used as an adjunct to CT scan. This Study will assess whether there are any potential safety concerns of the ProLung China Test when used to evaluate patients with a positive CT scan for lung cancer.

Interventions

None listed

Sponsors

Chinese Alliance Against Lung Cancer
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

1. Subject is male or female, age 18 to 80. 2. Subject has undergone CT scan of the lung(s) that indicates one or more nodules or lesions. 3. Subject's pulmonary nodule or lesion is greater than 4mm and smaller than 50mm. Size is determined by the largest nodule or lesion dimension identified from CT imaging. 4. Subject must be able to receive a ProLung China Test within 30 days of abnormal CT within 14 days prior to the tissue biopsy or surgical resection.

Exclusion criteria

1. Subject has an implanted electronic device in the chest. Subject receiving therapy for suspected chest infection such as fungal infection or tuberculosis. 2. Subject with diagnosed malignancy other than lung cancer who has 2 or more suspicious pulmonary nodules. 3. Subject has received an invasive medical or surgical procedure within the thoracic cavity within 30 days prior to the ProLung China Test or within the previous 14 days for a bronchoscopic procedure. 4. Subject presents with an anomalous physical or anatomical condition that precludes ProLung China Test measurement. 5. Subject will have undergone unusually strenuous exercise within 24 hours. 6. Subject who has significant systemic diseases such as uncontrolled diabetes, advanced heart failure, or a recent myocardial infarction, or other medical condition such as severe morbid obesity that in the judgment of the Principal Investigator would make him/her unsuitable for the Study.

Design outcomes

Primary

MeasureTime frameDescription
Safety and Efficacy of the ProLung China TestThe ProLung China Test will be performed within 30 days of a CT Scan that identifies a lung lesion suspicious for lung cancer and evaluated once a patient diagnosis is obtained.Demonstrate safety and efficacy in the risk stratification of patients with pulmonary lesions identified by CT that are suspicious for lung cancer.

Countries

China

Contacts

Primary ContactChunxue Bai, MD
bai.chunxue@zs-hospital.sh.cn18621170011
Backup ContactDawei Yang, MD
yang_dw@hotmail.com13564703813

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026